Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK. - Wikidata - wikimedia - TriplyDB

Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK.

Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK.

http://www.wikidata.org/entity/Q34737900

about

Antimicrobial bacteriophage-derived proteins and therapeutic applications Biochemical and biophysical characterization of PlyGRCS, a bacteriophage endolysin active against methicillin-resistant Staphylococcus aureus.Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient Pharmacokinetics and Tolerance of the Phage Endolysin-Based Candidate Drug SAL200 after a Single Intravenous Administration among Healthy Volunteers.Aeromonas punctata derived depolymerase improves susceptibility of Klebsiella pneumoniae biofilm to gentamicin.Learning from bacteriophages - advantages and limitations of phage and phage-encoded protein applications.Peptidoglycan hydrolases-potential weapons against Staphylococcus aureus Facing antibiotic resistance: Staphylococcus aureus phages as a medical tool.In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin.Efficient Killing of Planktonic and Biofilm-Embedded Coagulase-Negative Staphylococci by Bactericidal Protein P128.In silico modeling of the staphylococcal bacteriophage-derived peptidase CHAP(K).Potential of sequential treatment with minocycline and S. aureus specific phage lysin in eradication of MRSA biofilms: an in vitro study.Delivery of the endolysin Cpl-1 by inhalation rescues mice with fatal pneumococcal pneumonia.Bacteriophage-Derived Peptidase CHAP(K) Eliminates and Prevents Staphylococcal Biofilms.Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery Strategies.Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period.Characterization of the Lytic Capability of a LysK-Like Endolysin, Lys-phiSA012, Derived from a Polyvalent Staphylococcus aureus Bacteriophage.Potential for Bacteriophage Endolysins to Supplement or Replace Antibiotics in Food Production and Clinical Care.Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials

P2860

Q26781115-A8D7F5BC-D599-4F13-BDC9-920FBD44510A Q30009348-9BCA5715-8B35-48A1-8534-6AAC40FB8718 Q33622902-E14B06CA-3C1F-4024-BEF2-1BB91D8CCE5C Q33726692-E9238B3E-F87A-4702-B0DB-9D24F7F05D09 Q35660517-44D4A50C-F2ED-4D1C-B327-70B9F3BEF6F1 Q36676044-AE69A4F5-E700-49DA-9C91-672A965ABD40 Q38053102-481A75AF-4A7D-4332-8B91-11A97B51BAB1 Q38225652-791C5D58-C15C-40B9-A950-0410A7F9EE96 Q38282871-36BCB318-6263-42E0-9FEF-2929C2E4D8BA Q40192368-65AE81F4-D50A-4FA2-8C80-6F5ED515FE6D Q42055505-0033D6B7-FA1E-43AF-B169-C4C077C50B15 Q42160512-9640E0F9-D8C4-4A6D-ADE3-07DDB1E3A22C Q42264677-EF5F0612-B7C1-4180-B78C-23A5E9B0FEE4 Q43245858-759603EA-9C19-4035-9B56-2B5D3C6E6A45 Q46251747-D4BE9FB9-45E7-48BA-B022-C2D160D1D86D Q50800569-5CED7F78-9987-4B21-A60B-46EB8E8B4F32 Q51745780-E63F4F5F-C80B-4856-B445-D51BA5F8066D Q52679093-6C3EC028-D1D9-4610-9926-08A5DF5D8BBC Q59128002-07A3E25F-7B8C-436C-A71A-DAF447B7202E

P2860

Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK.

http://www.wikidata.org/entity/Q34737900

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK.

@ast

Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK.

@en

Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK.

@nl

type

label

Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK.

@ast

Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK.

@en

Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK.

@nl

prefLabel

Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK.

@ast

Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK.

@en

Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK.

@nl

P1433

Q34737900-F82169B2-F305-4DD5-86DD-3754B01675DE

P1476

Q34737900-4D5D26E9-B462-4711-96F3-25A527A25410

P2093

Q34737900-289EFEF9-4051-46FB-954B-09487801D7C6

Q34737900-34956192-2390-4C8E-8E5E-A80FE64F4F0D

Q34737900-50D3CDE0-A1B3-4CD2-8A1B-7F04E712F9AB

Q34737900-831E185C-2798-4E68-93E9-77705470988C

Q34737900-98799211-7061-4483-AC9B-8FB2DA40F011

Q34737900-D2C788BA-AD46-4FFA-A071-BBEE00F3526B

P2860

Q34737900-038D552E-80FF-428D-9714-F8A954A4707B

Q34737900-134698BF-8EB6-4FB4-AC12-CD6155AE4663

Q34737900-1700FDA6-4303-4900-9CE1-B4069896776E

Q34737900-21D9500B-7707-4712-81E0-7BB41158F6DB

Q34737900-281B4BD5-A9F4-4E4E-8DDB-28F9E0D7543E

Q34737900-31F4807B-F8B9-4D5B-801A-EA96E19EE373

Q34737900-4F90C20A-48BA-4101-AE15-E5A0A653CEE2

Q34737900-503D5AFC-B04C-4732-B2F3-FCD95005E8D4

Q34737900-63BB69DC-7764-4739-A1FB-44FEB3C54840

Q34737900-6603A7C1-720E-4554-A8A5-69A46B3589E9

P304

Q34737900-AC9FAE40-5D69-45E8-B094-469357613976

P31

Q34737900-B55E1539-C4DF-461C-BEFB-E9B2F9A0AF47

P356

Q34737900-2CACE2EE-42B9-413A-9148-8A4D502BD497

P407

Q34737900-3B4E0AF2-EBFE-46BF-8C3E-F3BC35956B78

P433

Q34737900-4DE986AB-0081-4D1F-A569-C0C58B18B6D5

P478

Q34737900-C573F75A-5444-417F-A21E-C8E184E75AC3

P577

Q34737900-52A9EBCF-A570-4D0F-B892-4D6FF9DED34D

P5875

Q34737900-E0E49F36-E1A5-4852-BBE4-50D27E4834E7

P698

Q34737900-D3FD3BB7-D566-421B-BE76-6EBE8A7A2BDA

P932

Q34737900-648C3596-D745-41D2-920E-6A16D6BFC056

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK.

@en

P2093

Gi Mo Jung

http://www.w3.org/2001/XMLSchema#string

Jee-Soo Son

http://www.w3.org/2001/XMLSchema#string

Sang Hyeon Kang

http://www.w3.org/2001/XMLSchema#string

Seong Jun Yoon

http://www.w3.org/2001/XMLSchema#string

Soo Youn Jun

http://www.w3.org/2001/XMLSchema#string

Yun-Jaie Choi

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and Enterococcus faecium

Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme

Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia

Multiple enzymatic activities of the murein hydrolase from staphylococcal phage phi11. Identification of a D-alanyl-glycine endopeptidase activity

Determination of minimum inhibitory concentrations

Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme

Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.

The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus

Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats

A bacteriolytic agent that detects and kills Bacillus anthracis.

P304

1764-1767

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01097-10

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49781761

http://www.w3.org/2001/XMLSchema#string

P698

21263051

http://www.w3.org/2001/XMLSchema#string

P932

3067193

http://www.w3.org/2001/XMLSchema#string